SCHEMBL5217367

SCHEMBL5217367

Clc1ccc(-c2ccccc2)c(-c2ccccc2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.47
LMNA P02545 3/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
GLA P06280 1/20 0.47
PKM P14618 1/20 0.45
L3MBTL1 Q9Y468 3/20 0.44
GAA P10253 1/20 0.44
CYP2A6 P11509 1/20 0.43
ADORA1 P30542 5/20 0.40
ADORA2A P29274 3/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
CTRC Q99895 2/20 0.38
ALOX15 P16050 1/20 0.38
PSMB5 P28074 1/20 0.38
PDE10A Q9Y233 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7905040 0.80 CYP2A6 (0.44) KDM4ELMNAALDH1A1HPGDSMN1; SMN2
SCHEMBL27550199 0.78 PDE10A (0.54) KDM4ELMNAALDH1A1HPGDSMN1; SMN2
SCHEMBL361449 0.77 PSMB5 (0.42) KDM4ELMNAALDH1A1HPGDSMN1; SMN2
SCHEMBL22919342 0.77 KDM4E (0.50) KDM4ELMNAALDH1A1HPGDSMN1; SMN2
SCHEMBL15955707 0.77 PDE10A (0.56) KDM4ELMNAALDH1A1HPGDSMN1; SMN2
SCHEMBL29533424 0.77 KDM4E (0.50) KDM4ELMNAALDH1A1HPGDSMN1; SMN2
SCHEMBL24810006 0.77 MAPK1 (0.41) KDM4ELMNAALDH1A1HPGDSMN1; SMN2
SCHEMBL18136468 0.77 LMNA (0.48) KDM4ELMNAALDH1A1HPGDSMN1; SMN2
SCHEMBL29972990 0.77 KDM4E (0.45) KDM4ELMNAALDH1A1HPGDSMN1; SMN2
SCHEMBL29972734 0.77 KDM4E (0.55) KDM4ELMNAALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7205302-B2 Anticoagulants; antilipemic agents; cardiovascular disorders NIPPON SHINYAKU CO., LTD. (JP) 2007-04-17 US disclosed
EP-1400518-B1 HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES NIPPON SHINYAKU CO LTD (JP) 2007-01-17 EP disclosed
US-20040102436-A1 Heterocyclic compound derivatives and medicines NIPPON SHINYAKU CO., LTD. (JP) 2004-05-27 US disclosed
EP-1400518-A1 HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES Nippon Shinyaku Co., Ltd. (JP) 2004-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102436-A1 Heterocyclic compound derivatives and medicines CNR2, CNR1, GPR55 KDM4E 1781/4885LMNA 2619/4885ALDH1A1 3260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.